⌕
Neurocrine Biosciences · NBIX · Nasdaq
Tenet 59 · Mixed
Compare
$167.40−1.18%At closeTenet 59 · Mixed
$167.40−2.00 (−1.18%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Neurocrine Biosciences (NBIX) Stock

Neurocrine Biosciences (NBIX) closed at $167.40 on Nov 13, 2026; its Tenet Score is 59 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

7 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$167.40
Nov 13, 2026
Market cap
$16.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
25.1×
price ÷ earnings
52-week range
122.14 – 186.12
low → high
Tenet Score
59/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Neurocrine Biosciences, Inc. scores 59/100. Mixed. Strongest on quality and growth, financial health is the soft spot, trading at 25× earnings versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
59/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
57
Quality
78
Health
34
Growth
66

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityBHealthDGrowthCMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
4.4×
price to book value
P/S
4.6×
price to fiscal 2025 sales
ROE
20%
return on equity
Operating margin
21.6%
fiscal 2025, before interest and tax
Net margin
19.0%
of revenue kept
Current ratio
2.04
current assets to liabilities
Net debt / EBITDA
−0.8×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroid…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 249 US ETFs · top wrappers by weightSee all ETFs holding NBIX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Neurocrine Biosciences in?

Neurocrine Biosciences is in the Healthcare sector and the Drugs industry.

What is Neurocrine Biosciences' Tenet Score?

Neurocrine Biosciences' Tenet Score is 59 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.